These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells. Li Y; Hu T; Chen T; Yang T; Ren H; Chen M Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165 [TBL] [Abstract][Full Text] [Related]
5. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853 [TBL] [Abstract][Full Text] [Related]
6. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601 [TBL] [Abstract][Full Text] [Related]
7. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681 [TBL] [Abstract][Full Text] [Related]
8. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations. Gao J; Meng Q; Zhao Y; Chen X; Cai L BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Sun W; Zu Y; Fu X; Deng Y Oncol Rep; 2017 Dec; 38(6):3347-3354. PubMed ID: 29130102 [TBL] [Abstract][Full Text] [Related]
10. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
11. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway. Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099 [TBL] [Abstract][Full Text] [Related]
12. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114 [TBL] [Abstract][Full Text] [Related]
13. CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment. Kawano Y; Iwama E; Tsuchihashi K; Shibahara D; Harada T; Tanaka K; Nagano O; Saya H; Nakanishi Y; Okamoto I Lung Cancer; 2017 Nov; 113():72-78. PubMed ID: 29110853 [TBL] [Abstract][Full Text] [Related]
15. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells. Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405 [TBL] [Abstract][Full Text] [Related]
16. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer. Mattheolabakis G; Ling D; Ahmad G; Amiji M Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390 [TBL] [Abstract][Full Text] [Related]
17. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin. Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715 [TBL] [Abstract][Full Text] [Related]
18. Downregulation of basic fibroblast growth factor increases cisplatin sensitivity in A549 non-small cell lung cancer cells. He L; Meng Y; Zhang Z; Liu Y; Wang X J Cancer Res Ther; 2018; 14(7):1519-1524. PubMed ID: 30589033 [TBL] [Abstract][Full Text] [Related]
19. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431 [TBL] [Abstract][Full Text] [Related]
20. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Liu X; Ma M; Duan X; Zhang H; Yang M Clin Transl Oncol; 2017 May; 19(5):587-592. PubMed ID: 27832473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]